Susan Moran

Dr. Moran has over 20 years of industry and academic experience, successfully leading clinical trials from Phase 1 to Phase 3, as well as NDA and MAA submissions for various investigational products including the successful approval of Nerlynx. Dr. Moran currently serves as the CMO of QED Therapeutics. Before joining QED, she was VP and Head of Clinical Development for Puma Biotechnology and previously held senior positions at Millennium and Genzyme. Dr. Moran has played roles in the development, registration, and post-marketing support of products for breast, prostate, and thyroid cancer, as well as multiple sclerosis and other disorders. She is a board-certified internist and has served on the faculty of the University of Pennsylvania School of Medicine and Harvard Medical School. Susan received her BA from the University of Virginia, MD from Duke University, and MS in Clinical Epidemiology from the University of Pennsylvania School of Medicine.